Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + actinomycin D
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
A combination chemotherapy regimen consisting of methotrexate and actinomycin D. This combination is primarily used in the treatment of gestational trophoblastic neoplasia (GTN), particularly low-risk GTN. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate and interfering with DNA synthesis. Actinomycin D is an antibiotic that binds to DNA and inhibits RNA synthesis. Together, these agents provide enhanced efficacy compared to either agent alone in treating GTN.
02
Targets
DHFR (Dihydrofolate reductase)DNANeuraminidase
Beyond the preview
Go deeper on methotrexate + actinomycin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + actinomycin D.